GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...

Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover Ozempic. More ...

GoodRx is collaborating with Novo Nordisk to offer its weight-loss drugs to self-paying patients at lower costs. The prescription-drug provider said Monday that all strengths of Ozempic and Wegovy ...